PAOG Cites Research On Hemp Compounds Effectiveness


Sandusky, OH, Jan. 25, 2022 (GLOBE NEWSWIRE) — PAO Group, Inc. (OTC Pink: PAOG) today cited recently published information on research indicating CBDA and CBGA, compounds found in hemp, “block a critical step in the process the [Covid] virus uses to infect people” (source).

“The two compounds were identified during a chemical screening by researchers at the Linus Pauling Institute at Oregon State University. The compounds bind to spike proteins found on the virus and blocked the spike protein from binding to sites in a human host, thereby preventing a step the pathogen uses to infect people” (source).

PAOG owns intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960). 

PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property.

PAOG’s CBD formulation, derived from a patented cannabis extraction process, is years in the making for the treatment of symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions PAOG is developing the CBD formulation with the intent of delivering an approved pharmaceutical treatment under the brand name RespRx.

PAOG considers the recent hemp compound research regarding Covid as potential validation of the respiratory benefits of RespRx, and also potentially beneficial in advancing PAOG’s ongoing research with RespRx.

PAOG currently markets its own independent line of CBD nutraceutical products under its “RX” label available for sale on North American Cannabis Inc.’s (OTC Pink: USMJ) ecommerce site www.usmj.com.

PAOG has recently announced the development of a new line of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA) now underway.

PAOG plans to publish a 2022 strategic update this Friday, January 28, 2022.

For more information on Puration, visit http://www.purationinc.com

Learn more about PAOG at www.paogroupinc.com.

Disclaimer:

This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.

For More Information Contact:

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

Jim DiPrima
888-272-6472
info@pao.group

Previous HEXO Provides Update on "The Path Forward"; Maintains #1
Next Proactive news headlines including Pfizer, Silverton